Clinical Trial

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Study acronym: FIL_DALYA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-05-31; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2022-09-14
Status change: Active, Not Recruiting → Not Yet Recruiting 2022-04-22
Status change: Not Yet Recruiting → Active, Not Recruiting 2021-12-17
Trial Details
NCT Number NCT04915248
Lead Sponsor Fondazione Italiana Linfomi - ETS
Collaborators: Janssen-Cilag S.p.A.
Conditions Plasmablastic Lymphoma
Enrollment 28 participants
Start Date 2022-07-11
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-02